Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
BMC Pulm Med ; 24(1): 321, 2024 Jul 04.
Artigo em Inglês | MEDLINE | ID: mdl-38965516

RESUMO

BACKGROUND: Patients with multiple myeloma are immunosuppressed due to both the disease itself and immunosuppressive therapies. Thus, when presenting with respiratory failure and pulmonary opacities, pneumonia must be considered. However, while rare, immunomodulating medications used in the treatment of multiple myeloma can also cause potentially life-threatening respiratory failure, a distinction which has important treatment implications. CASE PRESENTATION: An 80-year-old male with recently diagnosed multiple myeloma undergoing treatment with lenalidomide and daratumumab presented with acute, rapidly progressive hypoxic respiratory failure ultimately requiring intubation and mechanical ventilatory support. Imaging revealed bilateral pulmonary opacities, however infectious workup was negative, and he was ultimately diagnosed with lenalidomide-induced interstitial pneumonitis, a rare but serious adverse effect of this medication. He was treated with drug discontinuation and methylprednisolone, and quickly recovered. CONCLUSION: Lenalidomide is an immunomodulating medication used in the treatment of multiple myeloma, and is associated with rare but serious cases of drug-induced interstitial pneumonitis. Thus, if a patient receiving lenalidomide develops shortness of breath and/or hypoxia, drug-induced pneumonitis must be on the differential. Permanent drug discontinuation with or without corticosteroids is the mainstay of treatment, and patients are often able to fully recover, underscoring the need for early recognition of this condition.


Assuntos
Lenalidomida , Doenças Pulmonares Intersticiais , Metilprednisolona , Mieloma Múltiplo , Insuficiência Respiratória , Humanos , Lenalidomida/efeitos adversos , Mieloma Múltiplo/tratamento farmacológico , Doenças Pulmonares Intersticiais/induzido quimicamente , Masculino , Idoso de 80 Anos ou mais , Insuficiência Respiratória/induzido quimicamente , Metilprednisolona/uso terapêutico , Hipóxia/induzido quimicamente , Agentes de Imunomodulação/efeitos adversos , Tomografia Computadorizada por Raios X , Anticorpos Monoclonais
2.
Diagn Microbiol Infect Dis ; 109(2): 116251, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38492489

RESUMO

A 61-year-old male with subacute headache was found to have cryptococcal meningitis despite a negative BioFire FilmArray meningitis/encephalitis panel. This case underscores the importance of liberal cryptococcal antigen testing, and that a negative FilmArray panel is inadequate in excluding cryptococcal meningitis, particularly in a HIV-negative host.


Assuntos
Meningite Criptocócica , Reação em Cadeia da Polimerase , Humanos , Meningite Criptocócica/diagnóstico , Meningite Criptocócica/microbiologia , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase/métodos , Cryptococcus neoformans/isolamento & purificação , Cryptococcus neoformans/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA